CytomX Therapeutics Inc. | Ownership
Companies that own CytomX Therapeutics Inc.
Fidelity Management & Research Co.
5,752,663
13.06%
26,353
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
3,249,464
7.38%
377,032
0.01%
06/30/2018
BlackRock Fund Advisors
2,847,534
6.46%
653,544
0%
06/30/2018
The Vanguard Group, Inc.
2,041,258
4.63%
633,318
0%
06/30/2018
Perceptive Advisors LLC
1,921,715
4.36%
-287,097
0.99%
06/30/2018
SSgA Funds Management, Inc.
1,712,121
3.89%
559,163
0%
06/30/2018
Renaissance Technologies LLC
1,411,500
3.2%
450,300
0.03%
06/30/2018
Deerfield Management Company LP
729,948
1.66%
-23,374
0.47%
06/30/2018
Aquilo Capital Management LLC
649,763
1.48%
649,763
12.18%
06/30/2018
FIL Investment Advisors (UK) Ltd.
560,015
1.27%
130,090
0.01%
06/30/2018
| Address |
151 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.cytomx.com |
| Updated |
07/08/2019 |
| CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. |
